| Metformin inhibits proinflammatory responses and nuclear factor-κB in human vascular wall cells K Isoda, JL Young, A Zirlik, LA MacFarlane, N Tsuboi, N Gerdes, ... Arteriosclerosis, thrombosis, and vascular biology 26 (3), 611-617, 2006 | 675 | 2006 |
| Ly-6Chigh Monocytes Depend on Nr4a1 to Balance Both Inflammatory and Reparative Phases in the Infarcted Myocardium I Hilgendorf, LMS Gerhardt, TC Tan, C Winter, TAW Holderried, ... Circulation research 114 (10), 1611-1622, 2014 | 573 | 2014 |
| Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry H Winkels, E Ehinger, M Vassallo, K Buscher, HQ Dinh, K Kobiyama, ... Circulation research 122 (12), 1675-1688, 2018 | 460 | 2018 |
| CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1 A Zirlik, C Maier, N Gerdes, L MacFarlane, J Soosairajah, U Bavendiek, ... Circulation 115 (12), 1571-1580, 2007 | 282 | 2007 |
| Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY … KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ... The lancet Diabetes & endocrinology 7 (8), 618-628, 2019 | 259 | 2019 |
| First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension M Böhm, F Mahfoud, C Ukena, UC Hoppe, K Narkiewicz, M Negoita, ... Hypertension 65 (4), 766-774, 2015 | 237 | 2015 |
| Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial M Szarek, HD White, GG Schwartz, M Alings, DL Bhatt, VA Bittner, ... Journal of the American College of Cardiology 73 (4), 387-396, 2019 | 197 | 2019 |
| Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study A Zirlik, SM Abdullah, N Gerdes, L MacFarlane, U Schönbeck, A Khera, ... Arteriosclerosis, thrombosis, and vascular biology 27 (9), 2043-2049, 2007 | 168 | 2007 |
| Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial SJ Shah, BA Borlaug, ES Chung, DE Cutlip, P Debonnaire, PS Fail, ... The Lancet 399 (10330), 1130-1140, 2022 | 162 | 2022 |
| Empagliflozin in acute myocardial infarction: the EMMY trial D von Lewinski, E Kolesnik, NJ Tripolt, PN Pferschy, M Benedikt, ... European heart journal 43 (41), 4421-4432, 2022 | 157 | 2022 |
| Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation A Zirlik, C Bode Journal of thrombosis and thrombolysis 43 (3), 365-379, 2017 | 153 | 2017 |
| Innate response activator B cells aggravate atherosclerosis by stimulating T helper-1 adaptive immunity I Hilgendorf, I Theurl, LMS Gerhardt, CS Robbins, GF Weber, A Gonen, ... Circulation 129 (16), 1677-1687, 2014 | 152 | 2014 |
| Nicotinamide for the treatment of heart failure with preserved ejection fraction M Abdellatif, V Trummer-Herbst, F Koser, S Durand, R Adão, ... Science translational medicine 13 (580), eabd7064, 2021 | 134 | 2021 |
| TRAF-1,-2,-3,-5, and-6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells A Zirlik, U Bavendiek, P Libby, L MacFarlane, N Gerdes, J Jagielska, ... Arteriosclerosis, thrombosis, and vascular biology 27 (5), 1101-1107, 2007 | 131 | 2007 |
| Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study JA de Lemos, A Zirlik, U Schönbeck, N Varo, SA Murphy, A Khera, ... Arteriosclerosis, thrombosis, and vascular biology 25 (10), 2192-2196, 2005 | 129 | 2005 |
| Pathogenic Autoimmunity in Atherosclerosis Evolves From Initially Protective Apolipoprotein B100–Reactive CD4+ T-Regulatory Cells D Wolf, T Gerhardt, H Winkels, NA Michel, AB Pramod, Y Ghosheh, ... Circulation 142 (13), 1279-1293, 2020 | 127 | 2020 |
| CD40L and its receptors in atherothrombosis—an update NA Michel, A Zirlik, D Wolf Frontiers in cardiovascular medicine 4, 40, 2017 | 119 | 2017 |
| Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis—but does not affect immunity and thrombosis in mice D Wolf, JD Hohmann, A Wiedemann, K Bledzka, H Blankenbach, ... Circulation research 109 (11), 1269-1279, 2011 | 115 | 2011 |
| Renal denervation in high-risk patients with hypertension F Mahfoud, G Mancia, R Schmieder, K Narkiewicz, L Ruilope, M Schlaich, ... Journal of the American College of Cardiology 75 (23), 2879-2888, 2020 | 111 | 2020 |
| The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP) F Zhubi-Bakija, G Bajraktari, I Bytyçi, DP Mikhailidis, MY Henein, ... Clinical nutrition 40 (1), 255-276, 2021 | 98 | 2021 |
Peter StachonUniversity Heart Center Freiburg在 universitaets-herzzentrum.de 的电子邮件经过验证
